The effectiveness of BNT162b2 COVID-19 vaccine against infection with SARS-CoV-2 Omicron subvariants BA.4/5

By | October 27, 2022
Researchers evaluated the vaccine effectiveness of Pfizer-BioNTech’s BNT162b2 COVID-19 vaccines against SARS-CoV-2 Omicron BA.4/5.